Nuwellis, Inc. (NASDAQ:NUWE) Q4 2021 Earnings Conference Call March 1, 2022 9:00 AM ET Company Participants Matt Bacso ??? Investor Relations Nestor Jaramillo ??? President and Chief Executive Officer George Montague ??? Chief Financial Officer Conference Call Participants Jeffrey Cohen ??? Ladenburg Thalmann Brooks O???Neil ??? Lake Street Capital Markets Matt Bullock ??? Maxim Group Operator Good day and welcome to the Nuwellis Inc Fourth Quarter 2021 Earnings Call. At this time, all participants are in a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 001-35312 NUWELLIS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware No. 68-0533453 (State or Oth ...

Nuwellis, Inc. (NASDAQ:NUWE) Q3 2021 Earnings Conference Call November 9, 2021 9:00 AM ET Company Participants Matt Beckel - Gilmartin Group Nestor Jaramillo - President & CEO George Montague - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Brooks O'Neil - Lake Street Capital Markets Anthony Vendetti - Maxim Group Operator Good day and thank you for standing by. Welcome to the Nuwellis, Inc. Third quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 001-35312 NUWELLIS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware No. 68-0533453 (State or Other Juris ...

Nuwellis, Inc. (NASDAQ:NUWE) Q2 2021 Earnings Conference Call August 10, 2021 9:00 AM ET Company Participants Matthew Bacso - Gilmartin Group Nestor Jaramillo - President, CEO & Director George Montague - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Anthony Vendetti - Maxim Group Brooks O'Neil - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to the Nuwellis Inc. Second Quarter 2021 Earnings Conference Call. [Operator Instructions]. I would ...

Nuwellis, Inc. (NASDAQ:NUWE) Q1 2021 Earnings Conference Call May 12, 2021 7:00 AM ET Company Participants Matt Basco - Investor Relations Nestor Jaramillo - Chief Executive Officer Paul Wotta - Corporate Controller and Principal Accounting Officer Conference Call Participants Destiny Buch - Ladenburg Thalmann Anthony Vendetti - Maxim Group Brooks O???Neil - Lake Street Capital Operator Good day. Thank you for standing by, and welcome to the CHF Solutions, Inc. First Quarter 2021 Earnings Conference Call. [ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware No. 68-0533453 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) FORM 10‑Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file numb ...

For the Fiscal Year Ended: December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-35312 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 CHF SOLUTIONS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation o ...

chf solutions Corporate Presentation (NASDAQ: CHFS) March 2021 FOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCTION PROMOTION ©2021 CHF Solutions, Inc.1 Safe Harbor Statement Forward Looking Statement This presentation contains forward‐looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act, as amended regarding our plans, expectations, beliefs, estimates, goals and outlook for the future that are intended to be covered by t ...

Financial Data and Key Metrics Changes - Revenue for Q4 2020 was $2 million, representing a 49.5% increase from Q4 2019 and a 7.4% sequential increase from Q3 2020 [28] - For the full year 2020, revenue totaled $7.4 million, a 35% increase over 2019 [28] - Gross margins for Q4 2020 were 56.1%, up from 46.1% in Q3 2020 and 50.8% in Q4 2019 [29] - The net loss for Q4 2020 was $3.1 million, or $1.13 per share, compared to a net loss of $4.4 million, or $33.46 per share in Q4 2019 [31] Business Line Data and Key Metrics Changes - The revenue mix for Q4 2020 was 47% critical care, 27% pediatric, and 26% heart failure, with critical care revenue increasing significantly due to COVID-19 [13] - Pediatric utilization of the Aquadex therapy increased, with five new pediatric hospitals opened, bringing the total to 25 [15][16] - Heart failure revenues declined in the mid-teens compared to 2019, but are expected to increase in 2021 due to recent clinical evidence and anticipated CPT code approval [14] Market Data and Key Metrics Changes - The company anticipates a favorable trend in critical care utilization as awareness of the Aquadex system grows, particularly in treating non-COVID-19 patients [12] - The total addressable market for critical care and heart failure is estimated to be between $800 million and $1 billion each, while the pediatric market is estimated at around $150 million, totaling approximately $2 billion [67][69] Company Strategy and Development Direction - The company aims to position itself as the primary provider of ultrafiltration therapy for various medical professionals treating fluid overload [9] - A focus on expanding pediatric and critical care opportunities is evident, with a commitment to educating key opinion leaders in the pediatric community [15][51] - The company is investing in new technology, demonstrated by the filing of three patent applications in Q4 2020 [24][27] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about sales growth as healthcare returns to a new normal, despite challenges posed by the COVID-19 pandemic [9] - The company expects Q1 2021 revenues to increase in low single digits sequentially, with continued limited access to hospitals impacting traditional business [33] - Management believes that the synergetic effect of treating COVID-19 patients will positively influence the treatment of non-COVID-19 patients in critical care [71] Other Important Information - The company recognized a gain of $1.2 million related to the dissolution of an inactive subsidiary in Australia [31] - A pediatric registry was initiated to collect real-world evidence on the use of the Aquadex SmartFlow in pediatric patients, with the first patient expected to be enrolled in April 2021 [18] Q&A Session Summary Question: Trends in Q4 and 2021 expectations - Management indicated that Q4 was strong and expects similar trends for 2021, with a strong pipeline and increased utilization in ICUs [39] Question: Future pediatric center openings - Management anticipates the potential for 10 to 20 new pediatric centers in 2021, depending on hospital access [40] Question: Hospital access trends - Limited access to hospitals remains a concern, but management hopes for improvements as vaccinations increase [42] Question: Market potential in critical care, pediatric, and heart failure - The total addressable market is estimated at $2 billion, with critical care and heart failure each around $800 million to $1 billion, and pediatrics at approximately $150 million [67][69] Question: Impact of COVID-19 on business - Management believes COVID-19 has positively impacted the business by demonstrating the effectiveness of the Aquadex system in critical care settings [71] Question: Upcoming studies and milestones - Management highlighted the pediatric registry and upcoming clinical studies as significant events for 2021 [73]